文献速递乳腺癌

纳武利尤单抗联合卡铂和紫杉醇新辅助治疗早期三阴性乳腺癌的时机(BCT1902/IBCSG 61-20;Neo-N):一项非比较、开放标签、随机、2期试验

Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2025-01-01

Neo-N是一项在澳大利亚、新西兰和意大利14家医院开展的非比较、开放标签、随机2期试验,纳入110例早期三阴性乳腺癌患者,随机分为纳武利尤单抗导入组和同步组,均接受12周卡铂和紫杉醇化疗。导入组病理完全缓解率为51%(39-63),同步组为55%(43-66)。研究未支持化疗前导入纳武利尤单抗带来病理完全缓解优势的假设,但达到了较高的病理完全缓解率,支持更短疗程、不含蒽环类药物的方案。

要点

  • 导入组病理完全缓解率51%(39-63),同步组55%(43-66)。
  • 治疗相关3-4级不良事件导入组60%(32/53),同步组69%(38/55)。
  • 研究未支持化疗前导入纳武利尤单抗带来病理完全缓解优势的假设。

核心结论

  • 本研究未支持化疗前导入纳武利尤单抗与病理完全缓解优势相关的假设。
  • 达到了较高的病理完全缓解率,支持在新诊断三阴性乳腺癌患者中使用更短疗程、不含蒽环类药物的方案。
  • 未来需要试验将该方案与当前标准治疗进行比较。

研究设计与样本

  • Neo-N是一项研究者发起的、非比较、开放标签、随机、2期试验,在澳大利亚12家医院、新西兰1家和意大利1家开展。
  • 纳入年龄≥18岁、ECOG体能状态0-1、临床I期(cT1cN0)或II期(cT1cN1、cT2cN0-1或cT3cN0)、雌激素受体表达<1%、孕激素受体表达<10%、HER2阴性、既往未治疗的可手术乳腺癌且器官功能 adequate 的患者。
  • 按年龄分层,采用计算机生成序列和最小化算法中央随机1:1分配。
  • 导入组:纳武利尤单抗240 mg,2周后纳武利尤单抗360 mg和卡铂AUC5每3周一次,同步紫杉醇80 mg/m²每周一次,共12周。
  • 同步组:纳武利尤单抗360 mg和卡铂AUC5每3周一次,同步紫杉醇80 mg/m²每周一次,共12周,2周后纳武利尤单抗240 mg。

主要发现

  • 2020年7月6日至2022年4月1日,124例参与者入组,14例不合格,110例随机分配,108例纳入改良意向治疗分析(导入组53例,同步组55例)。
  • 中位随访12个月(IQR 7-18),所有患者均为女性,中位年龄49岁(IQR 43-60)。
  • 18例(17%)患者临床淋巴结阳性;37例(34%)临床I期,70例(65%)II期,1例(1%)III期。
  • 病理完全缓解率:导入组27/53(51% [39-63]),同步组30/55(55% [43-66])。
  • 治疗相关3-4级不良事件:108例中70例(65%),导入组32/53(60%),同步组38/55(69%);最常见为中性粒细胞计数降低(导入组25/53 [47%] vs 同步组28/55 [53%])、贫血(6/53 [11%] vs 10/55 [19%])、丙氨酸氨基转移酶升高(3/53 [6%] vs 3/55 [6%])。

关键数值与推荐

  • 病理完全缓解率:导入组51%(39-63),同步组55%(43-66)。
  • 治疗相关3-4级不良事件:导入组60%(32/53),同步组69%(38/55)。
  • 治疗相关严重不良事件:导入组13%(7/53),同步组36%(20/55)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究为非比较、开放标签设计。
  • 未来需要试验将该方案与当前标准治疗进行比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal scheduling of PD-1 inhibitors with neoadjuvant chemotherapy in patients with early triple-negative breast cancer is unknown. We aimed to investigate the activity of two differing schedules of neoadjuvant nivolumab initiation with 12 weeks of carboplatin and paclitaxel for this patient population. METHODS: Neo-N is an investigator-initiated, non-comparative, open-label, randomised, phase 2 trial conducted at 12 hospitals in Australia, one in New Zealand, and one in Italy. Participants had to be aged 18 years or older; have an Eastern Cooperative Oncology Group performance status of 0-1, clinical stage I (cT1cN0) or II (cT1cN1, cT2cN0-1, or cT3cN0), oestrogen receptor expression of less than 1%, and progesterone receptor expression of less than 10%; had to be HER2 negative; and have previously untreated operable breast cancer with adequate organ function. Participants were stratified according to age and randomly assigned (1:1) centrally using a computer-generated sequence with a minimisation algorithm to either nivolumab 240 mg then 2 weeks later nivolumab 360 mg and carboplatin AUC5 every 3 weeks with concurrent paclitaxel 80 mg/m2 once per week for 12 weeks (lead-in group) or concurrent nivolumab 360 mg and carboplatin AUC5 every 3 weeks with once per week paclitaxel 80 mg/m2 for 12 weeks then 240 mg nivolumab 2 weeks later (concurrent group). Data were collected from registration until the 100-day safety follow-up visit, and survival follow-up continues. The primary endpoint was pathological complete response (ypT0/Tis ypN0) at the time of surgery, analysed in each group separately and in all patients who received at least one dose of all three study treatment (modified intention-to-treat population). The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12619001308189, and EudraCT, 2019-003465-18, and is ongoing. FINDINGS: Between July 6, 2020, and April 1, 2022, 124 participants were enrolled and 14 were ineligible. 110 participants were randomly assigned and 108 were included in the modified intention-to treat analysis (53 in the lead-in group and 55 in the concurrent group). Median follow-up was 12 months (IQR 7-18). All patients were female with a median age of 49 years (IQR 43-60). 18 (17%) patients had clinically node-positive disease; 37 (34%) had clinical stage I, 70 (65%) had stage II, and one (1%) had stage III disease. The pathological complete response rate was observed in 27 (51% [39-63]) of 53 patients in the nivolumab lead-in group and in 30 (55% [43-66]) of 55 in the concurrent group. Treatment-related grade 3-4 adverse events occurred in 70 (65%; 32 [60%] of 53 in the lead-in group and 38 [69%] of 55 in the concurrent group) of 108 patients, with the most common being decreased neutrophil count (25 [47%] of 53 in the lead-in group vs 28 [53%] of 55 in the concurrent group), anaemia (six [11%] vs ten [19%]), and increased alanine aminotransferase (three [6%] vs three [6%]). Serious adverse events were reported in 16 (30%) patients in the lead-in group and 26 (47%) in the concurrent group. Treatment-related serious adverse events occurred in seven (13%) patients in the lead-in group and 20 (36%) in the concurrent group. No treatment-related deaths occurred during the study. INTERPRETATION: While this study did not support the hypothesis that lead-in nivolumab before chemotherapy was associated with a pathological complete response advantage, high pathological complete response rates were reached supporting shorter duration, non-anthracycline regimens in patients with newly diagnosed triple-negative breast cancer. Future trials are warranted to compare this regimen with the current standards of care. FUNDING: Breast Cancer Trials and Bristol Myers Squibb.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Zdenkowski N, Kuper-Hommel MJJ, Niman SM, et al. Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial. Lancet Oncol. 2025. PMID: 40049198. doi:10.1016/S1470-2045(24)00757-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。